glp 1 drugs for parkinson's disease Are GLP-1 diabetes like Ozempic coming disease? — Parkinson Secrets GLP-1 does not slow Parkinson's

But is the idea that they prevent dementia true

A comprehensive literature search was conducted across the PubMed, Embase, and Google Scholar databases for peer-reviewed articles published from inception through June 15, 2026, focusing on the landmark SURPASS, SURMOUNT, and SUMMIT trial programs, relevant cardiorenal post hoc analyses, emerging body recomposition trials, and real-world cohort-switching protocols

Conclusion A population pharmacokinetic model incorporating allometric scaling was developed to simultaneously describe the PK of semaglutide in all animal species and predict its PK in humans

The magnitude of the benefits of GLP-1RA and SGLT-2 inhibitors on MACE are similar, ranging from 12 to 14% reduction of risk, but only GLP-1RA may reduce the risk of stroke